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Abstract
Background: Usher syndrome (USH) combines sensorineural deafness with blindness. It is inherited in an
autosomal recessive mode. Early diagnosis is critical for adapted educational and patient management choices, and
for genetic counseling. To date, nine causative genes have been identified for the three clinical subtypes (USH1,
USH2 and USH3). Current diagnostic strategies make use of a genotyping microarray that is based on the
previously reported mutations. The purpose of this study was to design a more accurate molecular diagnosis tool.
Methods: We sequenced the 366 coding exons and flanking regions of the nine known USH genes, in 54 USH
patients (27 USH1, 21 USH2 and 6 USH3).
Results: Biallelic mutations were detected in 39 patients (72%) and monoallelic mutations in an additional 10
patients (18.5%). In addition to biallelic mutations in one of the USH genes, presumably pathogenic mutations in
another USH gene were detected in seven patients (13%), and another patient carried monoallelic mutations in
three different USH genes. Notably, none of the USH3 patients carried detectable mutations in the only known
USH3 gene, whereas they all carried mutations in USH2 genes. Most importantly, the currently used microarray
would have detected only 30 of the 81 different mutations that we found, of which 39 (48%) were novel.
Conclusions: Based on these results, complete exon sequencing of the currently known USH genes stands as a
definite improvement for molecular diagnosis of this disease, which is of utmost importance in the perspective of
gene therapy.
Background
Usher syndrome (USH, MIM 276900, MIM 276905,
MIM 605472) combines sensorineural hearing impair-
ment with retinitis pigmentosa [1]. In addition, vestibu-
lar dysfunction can be observed in some patients. USH
occurs in ~1/20 000 individuals, and represents 50% of
all monogenic deaf-blindness cases. Three clinical sub-
types can be distinguished. USH type I (USH1) is char-
acterized by severe to profound congenital hearing
impairment, prepubertal onset of retinitis pigmentosa,
and vestibular arreflexia. USH type II (USH2) combines
congenital moderate to severe hearing impairment,
onset of retinitis pigmentosa in the first or second dec-
ade of life, and absence of vestibular dysfunction.
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genital or early onset progressive hearing impairment,
variable age of onset and severity of retinitis pigmentosa,
and variable vestibular dysfunction. USH is inherited in
the autosomal recessive mode, and is genetically hetero-
geneous. To date, nine causative genes have been identi-
fied. Mutations in MYO7A [2], USH1C [3,4], CDH23
[5,6], PCDH15 [7,8] and USH1G [9] cause USH1, muta-
tions in USH2A [10], VLGR1 [11] and WHRN [12]
cause USH2, and mutations in USH3A [13] cause
USH3. Mutations in MYO7A [14-16], USH1C [17,18],
CDH23 [6], PCDH15 [17] and WHRN [19] have also
been reported in patients affected by hearing impair-
ment only, while USH2A is also involved in isolated reti-
nitis pigmentosa [20].
The USH1 genes encode the actin-based motor pro-
tein myosin VIIa (USH1B), two Ca
2+-dependent trans-
membrane adhesion proteins, cadherin-23 (USH1D) and
protocadherin-15 (USH1F), the PDZ domain-containing
submembrane protein harmonin (USH1C), and the scaf-
fold protein sans that contains ankyrin repeats and a
sterile alpha motif domain (USH1G). The USH2 genes
encode two large transmembrane proteins, usherin
(USH2A) and VLGR1 (very large G protein-coupled
receptor, USH2C), and the PDZ domain-containing sub-
membrane protein whirlin (USH2D). Finally, USH3A
encodes the four-transmembrane-domain protein clarin-
1. Each USH gene encodes several protein isoforms,
except MYO7A and USH1G.
Absence of an early diagnosis of USH is devastating. In
USH1 patients, sign language becomes a less and less
efficient mode of communication as the visual defect pro-
gresses, and ultimately, the patients may become unable
to communicate except by tactile exchanges. As a result
of an early diagnosis of USH1, early bilateral cochlear
implantation allowing the development of an oral mode
of communication and early physical therapy for vestibu-
lar disorders are strongly recommended. The early diag-
nosis is also critical for genetic counseling, educational
orientation and therapeutic management, which may
include retinal gene therapy in the future [21,22]. So far,
a comprehensive molecular diagnosis of USH has been
hampered both by the genetic heterogeneity of the dis-
ease and the large number of exons for six out of the
nine known USH genes. The five USH1, three USH2, and
one USH3 genes are collectively composed of 183, 173,
and five coding exons, respectively [23].
Cremers and collaborators have developed a genotyp-
ing microarray for USH, based on the arrayed primer
extension (APEX) method. This approach, in a first ver-
sion, included the analysis of 298 USH-associated
sequence variants located in eight genes: MYO7A,
USH1C, CDH23, PCDH15, USH1G, USH2A, VLGR1 and
USH3A [24]. The mutations detected by the array
subsequently increased, and currently include 612 pre-
viously identified disease-associated variants in the nine
known USH genes [25]. The selected variants were pre-
valent in the following European countries: Belgium,
Denmark, UK, Germany, Italy, Spain, Switzerland and
Netherlands, and in the USA. The authors could prove
that the chip, with >98% accuracy, is an adaptable and
affordable mutation screening tool. However, the effi-
ciency of the chip was both dependent on the USH sub-
type examined and the studied population, ranging from
30% in the USA to 80% in Denmark in USH1 cases [24].
Recently, Jaijo et al., using an intermediate genotyping
microarray (429 reported mutations), found mutations in
only 34% of the patients tested [26], which is indicative of
a large number of private mutations. Therefore, improve-
ment of the molecular diagnosis is needed.
Alternative strategies include direct sequencing of
USH gene coding exons [27-30]. To determine the most
efficient strategy, some critical information is, however,
still lacking. Is the clinically diagnosed USH subtype a
reliable indication of the causative gene? What is the
frequency of digenic/oligogenic inheritance in this dis-
ease? Such a mode of inheritance is suggested by the
colocalization and direct in vitro interactions of the
USH1 proteins [31-39], and of the USH2 proteins
[40,41]. In a few USH1 patients, digenic inheritance
involving PCDH15 and CDH23 has indeed been
reported [42]. To address these issues, we undertook a
large-scale mutation screening of all currently known
USH genes in a cohort of 54 USH patients.
Subjects and Methods
Subjects
Fifty-four unrelated Caucasian patients including five
patients originating from Maghreb were included in the
study. Most patients were referred to Armand-Trous-
seau Children’s Hospital in Paris, and other patients
were referred to genetic consultations throughout
France. All patients were tested by audiograms and elec-
troretinogram. Auditory function was assessed by oto-
scopy, tympanometry, standard pure tone audiometry,
and recording of auditory brainstem responses and otoa-
coustic emissions. The cochlear origin of the hearing
impairment was confirmed by auditory brainstem
responses, and by the absence of otoacoustic emissions.
USH was diagnosed on the basis of simultaneous occur-
rence of sensorineural deafness and retinal degeneration.
Scrutiny of the time of onset, evolution and severity of
the hearing impairment, and quality of vestibular
responses enabled to assign the patients to one of the
three clinical types of the disease [43]. Patients were
considered as USH3 when their hearing impairment had
been detected in adulthood and showed clear progres-
siveness. For these patients, vestibular function
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of the patients were available for the study, and had
normal hearing. This study was approved by the local
ethics committee, and written consent for genetic test-
ing was obtained from adult probands or parents of
minor patients.
PCR amplification and sequencing
Genomic DNA was extracted from peripheral blood
using standard procedures. The coding exons and flank-
ing intronic sequences of all nine USH genes were
amplified and sequenced using forward and reverse pri-
mers (primer sequences and conditions available upon
request). We also searched for the previously reported
684 kb deletion in PCDH15 using the reported primers
[44]. Sequences were run on ABI 3100 DNA analyzer,
and assembled using ABI Prism Seqscape 2.1 to Gen-
bank reference sequences [45].
Control DNAs
The genomic DNAs from 153 unaffected Caucasian
control individuals were sequenced (306 control alleles).
For the mutations possibly involved in oligogenic inheri-
tance, DNAs from 333 healthy unrelated Caucasian indi-
viduals were used as controls. For the mutations present
in patients originating from Maghreb, the DNAs from
95 Moroccan and 91 Algerian healthy unrelated indivi-
duals were used as controls.
In silico analysis of sequence variants
The SIFT (Sorting Intolerant from Tolerant) [46] and
Polyphen [47] software programs were used to predict
the influence of any amino acid substitution on the pro-
tein structure and function. NetGene2 [48] and “Splice
site prediction by neural network” [49] interfaces were
used to predict the influence of nucleic acid substitu-
tions on splice donor and acceptor sites. Presence of
Exonic Splicing Enhancers (ESE) was detected using ESE
Finder [50].
Segregation analysis
Segregation of all sequence variants identified in the
patients was studied by sequencing the corresponding
DNA fragments in the parents and other relatives. In all
patients carrying two distinct mutations in a given USH
gene, biallelic transmission was confirmed by the segre-
gation analysis.
Mutation nomenclature
The mutation nomenclature complies with the mutation
nomenclature correction tool Mutalyzer [51] according
to the HGVS Guidelines & Recommendations [52]. The
+1 position in mutation numbering corresponds to the
A of the ATG initiation codon.
Protein Accession numbers
MYO7A, [Swiss-Prot:Q13402]; USH1C, [Swiss-Prot:
Q7RTU8]; CDH23, [Swiss-Prot:Q9H251]; PCDH15-CD1,
[Swiss-Prot:Q96QU1]; PCDH15-CD2,[ N C B I - R e f S e q :
NP_001136241.1]; PCDH15-CD3, [Swiss-Prot:C9J4F3];
USH1G, [Swiss-Prot:Q495M9]; USH2A, [Swiss-
Prot:075445]; VLGR1, [Swiss-Prot:Q8WXG9]; WHRN,
[Swiss-Prot:Q9P202]; USH3A, [Swiss-Prot:P58418] and
[Swiss-Prot:P58418-1] for “a” and “c” variants, respectively.
Results
Mutation analysis: high prevalence of novel mutations
We analyzed the nine USH genes in a cohort of 54
French patients, of whom 27 were affected by USH1, 21
by USH2, and six by USH3. From the patient and parent
questionnaires, consanguinity was established for nine
families (see Table 1). Sequencing of the coding and
non coding exons of all currently known USH genes
was carried out in every patient. Screening for predicted
causative missense and splice site mutations was per-
formed using prediction software programs. Amino acid
substitutions were considered likely to be pathogenic
missense mutations when predicted possibly or probably
deleterious by Polyphen software and not-tolerated by
the SIFT program. Nucleotide variations were consid-
ered likely to be splice site mutations when predicted
highly confident donor or acceptor site mutations by
Netgene2 and “Splice site prediction by neural network”
programs. These sequence variants were ultimately clas-
sified as presumably pathogenic mutations only if the
affected amino acid residues were evolutionarily con-
served (Additional file 1 Figures S1 to S3) and/or these
variants were not found in the control individuals (see
Subjects and Methods).
A total of 81 distinct, presumably pathogenic muta-
tions were detected, specifically, 16 nonsense mutations,
five nucleotide duplications, 17 frame-shifting deletions,
seven splicing defect-causing mutations, 34 missense
mutations, and one isocoding variation. Thirty-nine
(48%) of these mutations, i.e. 27% to 100% of the muta-
tions found in each USH gene, had not been previously
reported (Tables 2, 3 and 4, Figure 1). In addition, 103
amino acid substitutions were classified as presumably
nonpathogenic sequence variants, including 33 new var-
iants and six variants that had previously been reported
as pathogenic mutations (Table 5). Numerous, presum-
ably neutral, isocoding and intronic variants were also
observed (listed in Additional file 2, Table S1).
Twenty-six pathogenic or presumably pathogenic
mutations in MYO7A were found in 19 patients, specifi-
cally, eight nonsense mutations, one nucleotide duplica-
tion, five nucleotide deletions, four splice site mutations,
and eight missense mutations. Seven of these mutations
had not been previously reported, including two
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Genes MYO7A USH1C CDH23 PCDH15 USH1G USH2A VLGR1 WHRN USH3A
Patient USH
type
U37 I [p.R666X] + [p.
E1917X]
U57 I [p.C1198X]+
[p.R1240Q]
P0485 I [p.Q1798X] +
[p.E1917X]
U14 C I [p.R972X] + [p.
R972X]
U9 C I [p.K164X] +
[p.K164X]
U36 I [p.R2024X] +
[p.G519D]
[p.R1060W]
U20 I [p.R669X] + [p.
R1883Q]
P0505 I [p.Q1798X] +
[p.A2009fsX32]
S1556 C I [p.H133fsX7]
+ [p.
H133fsX7]
S1295 C I [p.
Y1302fsX97]
+ [p.
Y1302sX97]
[p.G1301V] [p.Q5459H]
P0504 I [p.D75fsX31] +
[p.R1240Q]
[p.R357W]
U45 I [p.D75fsX31] +
[p.T165M]
P0411 C I [c.2283-1G>T]
+ [c.2283-
1G>T]
[p.D4707Y]
P0070 I [p.G163R] + [p.
A198T]
P0052 I [c.1690
+1G>A] + [p.
F1963del]
U3 I [p.L2186P] [p.L16V] [p.C3307W]
DID C I [p.
R80fsX69] +
[p.
R80fsX69]
[p.R3043W]
U47 I [p.
R80fsX69] +
[p.R103H]
P0469 I [p.
E2135fsX3]
+ [c.6050-
9G>A]
S1212 I [p.R1379P] +
[p.D2639G]
U38 I [p.R991X]
+ [p.
R991X]
S1530 I [p.
R1273S]
P0257 I [p.W38X]
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S1273 I [p.
D29fsX29] +
[p.
D29fsX29]
U46 I
U50 I
S1823 C I
P0486 II [p.A457V] +
[p.K269del]
U6 II [p.E3562X] +
[p.E767fsX21]
U24 II [p.P1220L] [p.S1307X] +
[p.C536R]
U48 II [p.W3955X] +
[p.
R2509fsX19]
P0483 II [p.E1492X] +
[p.T3571M]
P0418 II [p.K268R] [p.S5030X]
U56 C II [p.
T2991fsX61]
+ [p.
T2991fsX61]
U42 II [p.E767fsX21] +
[p.
Y4128fsX24]
P0449 II [p.E767fsX21] +
[p.C575Y]
P0493 II [p.H308fsX16]
+ [p.T4809I]
P0432 II [p.R1189W] [p.
M1344fsX42]
U51 II [p.V218E] + [p.
R317R]
P0511 II [p.T3571M] +
[p.T352I]
U49 II [p.E4321X] +
[p.Q753fsX8]
P0473 II [p.P522fsX8]
+ [p.
M5890fsX10]
[p.S11R]
U58 II [p.F112fsX29]
+ [p.H3399P]
P0463 II [p.
E4186fsX17]
U10 II
U53 II [p.
P246fsX13] +
[p.
P246fsX13]
U19 C II [p.H755Y]
P0426 II
U21 III [p.Y1730fsX6]
+ [c.10586-
1G>C]
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Page 5 of 19nonsense mutations (p.K164X,p . C 1 1 9 8 X ) ,an u c l e o t i d e
duplication (c.397dupC; p.H133fsX7), a nucleotide dele-
tion c.3904delT (p.Y1302fsX97), a nucleotide substitu-
tion (c.1690+1G>A) predicted to alter the splice donor
site of intron 14, and two missense mutations (p.K268R
and p.P1220L) that change amino acid residues located
in the motor head and the first MyTH4 domain of the
myosin VIIa tail, respectively (Tables 2, 3 and Figure 1).
Three distinct pathogenic or presumably pathogenic
mutations in USH1C were detected in three patients, spe-
cifically, a nucleotide duplication (c.238_239dupC; p.
R80fsX69) already reported in several patients [3,4,27,53],
a known missense mutation (p.R103H) affecting an
amino acid residue located in the PDZ1 domain of the
protein [27], and a novel missense mutation (p.R357W),
predicted to affect the first coiled-coil domain of the pro-
tein. These mutations are expected to affect the three
classes of harmonin isoforms (Tables 2, 3, Figure 1) [4].
Eight pathogenic or presumably pathogenic mutations
in CDH23 were found in six patients, specifically, a pre-
viously reported mutation that affects splicing (c.6050-
9G>A) [54], a novel nucleotide deletion (c.6404_64
05delAG; p.E2135fsX31), and six missense mutations
[55,56], four of which (p.R1189W, p.R1379P, p.D2639G,
and p.R3043W) had not been previously reported. They
affect amino acid residues located in the 11
th,1 3
th and
25
th cadherin repeat and the extracellular region adja-
cent to the transmembrane domain (3065-3085), respec-
tively (Tables 2, 3 Figure 1). Intriguingly, the p.R1060W
mutation, which affects a residue in the 10
th cadherin
repeat that belongs to a canonical motif (DRE) predicted
to bind Ca
2+ [57], has previously been reported in an
isolated form of deafness, DFNB12 (cited in Astuto
et al. [55]).
T w op a t h o g e n i co rp r e s u m a b l yp a t h o g e n i cm u t a t i o n s
in PCDH15, specifically, a nonsense mutation (p.R991X)
[27] and a novel missense mutation (p.R1273S), were
found in two patients. The missense mutation affects an
amino acid residue located immediately after the 11
th
cadherin repeat (Tables 2, 3, Figure 1). The large geno-
mic rearrangement in PCDH15 previously reported by
Le Guedard et al. [44] was not detected in this group of
patients.
Three pathogenic or presumably pathogenic mutations
in USH1G were found in three patients, specifically, an
already reported nonsense mutation (p.W38X) [58], a
novel nucleotide duplication (c.84dupC; p.D29fsX29),
and a novel sequence variant (c.46C>G; p.L16V). This
variant was absent from the control DNAs (0/666
alleles) and, according to the prediction software pro-
grams (NetGene2 and ESE finder), should create a splice
donor site resulting in a premature stop codon at codon
position 17 (Tables 2, 3; Figure 1).
T w e n t y - f i v ep a t h o g e n i co rp r e s u m a b l yp a t h o g e n i c
mutations in USH2A were found in 17 patients includ-
ing three USH3 patients, specifically, five nonsense
mutations, one nucleotide duplication, six nucleotide
deletions [59], two splice site mutations, 10 missense
mutations, and one isocoding variation possibly creating
a splice donor site (Tables 2, 3). All these mutations
affect the extracellular region of usherin (Figure 1). Nine
mutations had not been previously reported, specifically,
five frame-shifting deletions (c.4030_4037del
ATGGCTGG/p.M1344fsX42, c.5189_5199delATATGT
TTCAT/p.Y1730fsX6, c.7522delT/p.R2509fsX19, c.89
70_8971delCA/p.T2991fsX61, and c.12381_12382delCT/
p.Y4128fsX24), one splice acceptor site mutation
(c.10586-1G>C) that is expected to result in exon 54
skipping and premature termination of the protein, and
three missense mutations (p.C575Y, p.G1301V, p.
C3307W) that affect amino acid residues located in the
14
th fibronectin type III domain and the trideca-di-
cysteine domain (residue 3192 to 3371) between the
18
th and the 19
th fibronectin type III domains (Figure
1). Notably, the isocoding mutation (c.949C>A; p.
R317R) has been predicted to be pathogenic by Pen-
nings [60] and considered as nonpathogenic by Dreyer
[28]. Segregation analysis in our family was compatible
with a pathogenic effect of this mutation (Additional file
1 Figure S4).
E l e v e np a t h o g e n i co rp r e s u m a b l yp a t h o g e n i cm u t a -
tions in VLGR1 were detected in eight patients including
two USH3 patients. All were novel mutations, specifi-
cally, a nonsense mutation (p.E4321X), a nucleotide
duplication (c.1563dupT; p.P552fsX8), four nucleotide
deletions (c.333_334delTT/p.F112fsX29, c.2258_2270del
Table 1 Genotypes of USH patients (Continued)
U30 III [p.E767fsX21] +
[p.R303H]
S1226 III [p.G2752R] +
[c.5776+1G>A]
P0239 III [p.N4885S]
P0484 III [p.D1944N]
P0069 III [p.R379W]
Novel mutations are in bold. C (2
nd column) denotes consanguinity.
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Gene Nucleotide change Exon Amino acid change Frequency
in
USH alleles
(×/108)
Frequency in
control
alleles
Patient origin
& reference
MYO7A
223delG 4 D75fsX31 2 Australia, Italy, France [78]
397dupC 5 H133fsX7 2 This study
490A>T 6 K164X 2 This study
592G>A 6 A198T + splice
defect
1 0/306 Algeria [27]
1556G>A 14 G519D/splice defect 1 0/306 USA, France [63]
1690+1G>A 14 Splice defect 1 This study
1996C>T 17 R666X 1 Great Britain, Denmark [62]
2005C>T 17 R669X 1 USA [24]
2283-1G>T 20 Splice defect 2 Algeria [27]
2914C>T 24 R972X 2 Pakistan [79]
3594C>A 28 C1198X 1 This study
3904delT 30 Y1302fsX97 2 This study
5392C>T 39 Q1798X 2 Denmark, German, Great Britain/France
[62]
5749G>T 42 E1917X 2 unknown [80]
6025delG 44 A2009fsX32 1 Spain [63]
6070C>T 45 R2024X 1 unknown [80]
USH1C
238_239dupC 3 R80fsX69 3 Pakistan, Europe, Guinea [4]
CDH23
6050-9G>A 46 Splice defect 1 Germany [54]
6404_6405delAG 47 E2135fsX31 1 This study
PCDH15
2971C>T 22 R991X 2 France [27]
USH1G
84dupC 1 D29fsX29 2 This study
113G>A 1 W38X 1 USA [58]
USH2A
920_923dupGCCA 6 H308fsX16 1 Denmark [81]
2299delG 13 E767fsX21 4 Europe, USA, Africa, China [10]
3920C>G 18 S1307X 1 France [82]
4030_4037delATGGCTGG 18 M1344fsX42 1 This study
4474G>T 21 E1492X 1 Spain [83]
5189_5199delATATGTTTCAT 26 Y1730fsX6 1 This study
5776+1G>A 28 Splice defect 1 Norway [28]
7522delT 40 R2509fsX19 1 This study
8970_8971delCA 45 T2991fsX61 2 This study
10586-1G>C 54 Splice defect 1 This study
10684G>T 54 E3562X 1 Denmark, Norway [28]
11864G>A 61 W3955X 1 Netherlands [84]
12381_12382delCT 63 Y4128fsX24 1 This study
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c.12552_12553delGG/p.E4186fsX17), and
c.17668_17669delAT/p.M5890fsX10), and five missense
mutations (p.D1944N, p.H3399P, p.D4707Y, p.N4885S,
p.Q5459H) that all affect amino acid residues located in
the large extracellular region of the protein, between the
13
th and 14
th b-Calx domains, in the 4
th Epilepsy Asso-
ciated Repeat domain, in the 32
nd b-Calx domain,
between the 32
nd and 33
rd b-Calx domains, and in the
35
th b-Calx domain, respectively (Tables 2, 3, Figure 1).
Three pathogenic or presumably pathogenic mutations
in WHRN were detected in three patients including one
USH3 patient, specifically, a novel deletion (c.737delC;
p.P246fsX13), and two novel missense mutations (p.
S11R and p.R379W) that affect amino acid residues
located in the N-terminal Ala/Gly/Ser-rich stretch (aa 9-
31) and immediately after the PDZ2 domain, respec-
tively (Tables 2, 3, Figure 1). Notably, these missense
mutations only affect the longer whirlin isoform [19],
which is a component of the ankle link molecular com-
plex together with VLGR1 and usherin [40,41].
No mutations in USH3A were detected in our series
of USH patients.
Transmission modes: evidence for digenic/oligogenic
inheritance in some patients
We found mutations in 49 out of 54 (91%) USH
patients, specifically, in 24 out of 27 (89%) USH1
patients, 19 out of 21 (90%) USH2 patients, and all six
(100%) USH3 patients (see Table 1). Mutations in
MYO7A, USH1C, CDH23, PCDH15,a n dUSH1G,w e r e
found in 55%, 7%, 7%, 7%, and 4% of the USH1 cases,
respectively. Mutations were detected on both alleles in
21 USH1 patients (including the six consanguineous
families), and on one allele in the remaining three
USH1 patients. Moreover, one of these patients (U3)
harboured monoallelic, presumably pathogenic muta-
tions in two different USH1 genes (see below).
Mutations in USH2A, VLGR1 and WHRN were found in
57%, 19% and 9.5% of the USH2 cases, respectively.
Notably, one USH2 patient (P0486) carried biallelic
mutations in MYO7A. Mutations were detected on both
alleles in 15 USH2 patients (including a consanguineous
family), and on one allele in the remaining four USH2
patients. Finally, as regards the USH3 patients, biallelic
mutations in USH2A and monoallelic mutations in
VLGR1 or WHRN were found in three patients, two
patients, and one patient, respectively.
One USH1 and two USH2 patients were heterozygotes
for mutations in two or three USH genes, suggesting a
possible digenic/oligogenic inheritance of the syndrome.
In the USH2 patients, however, segregation analysis did
not support digenic inheritance. Patient P0418 carries a
nonsense mutation in USH2A (p.S5030X) and a mis-
sense mutation in MYO7A (p.K268R), but his brother,
who is also clinically affected, does not carry the
MYO7A mutation. Patient P0432 has a
c.4030_4037delATGGCTGG (p.M1344fsX42) mutation
in USH2A and a missense mutation in CDH23 (p.
R1189W), but his father, who has neither deafness nor
retinitis pigmentosa, also carries these two mutations,
and his clinically affected sister does not carry the muta-
tion in CDH23. In the USH1 patient, we found three
presumably pathogenic mutations in MYO7A
(c.6657T>C), USH1G (c.46C>G; p.L16V) and USH2A
(c.9921T>G). Her father carries the mutations in
MYO7A and USH2A without displaying symptoms of
the disease, whilst her unaffected mother carries the
mutation in USH1G. The mutations in MYO7A, USH1G
and USH2A were not found in 666 control alleles. Of
the four siblings, the affected girl is the only one who
carries the mutations in MYO7A and USH1G,a n d ,a l l
the more, the mutations in the three genes (Figure 2).
Therefore, a combination of monoallelic mutations in
t h r e eU S Hg e n e sm a yb er e s p o n s i b l ef o rt h ed i s e a s ei n
this patient.
Table 2 Pathogenic DNA variants (Continued)
15089C>A 70 S5030X 1 France [66]
VLGR1
333_334delTT 3 F112fsX29 1 This study
1563dupT 9 P522fsX8 1 This study
2258_2270delAAGTGCTGAAATC 12 Q753fsX8 1 This study
12552_12553delGG 62 E4186fsX17 1 This study
12961G>T 64 E4321X 1 This study
17668_17669delAT 82 M5890fsX10 1 This study
WHRN
737delC 2 P246fsX13 2 This study
Novel mutations are in bold.
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Page 8 of 19Table 3 Presumably pathogenic DNA variants
Gene Nucleotide
change
Exon Amino acid
change
Protein domain Frequency
in
USH alleles
(×/108)
Frequency in
control
alleles
Patient origin
& reference
MYO7A
487G>C 6 G163R Motor head 1 0/306 Algeria [27]
494C>T 6 T165M Motor head 1 0/306 Great Britain, France [58]
803A>G 8 K268R Motor head 1 0/306 This study
805_807delAAG 8 K269del Motor head 1 0/306 Italy, France [63]
1370C>T 13 A457V Motor head 1 0/306 Ireland, France [63]
3659C>T 29 P1220L MyTH4 (1) 1 0/666 This study
3719G>A 29 R1240Q MyTH4 (1) 2 0/306 Denmark, Great Britain/France
[62]
5648G>A 41 R1883Q MyTH4 (2) 1 0/306 USA [58]
5887_5889delTTC 43 F1963del FERM (2) 1 Europe, USA [24]
6657T>C 48 L2186P FERM (2) 1 0/666 France [85]
USH1C
308G>A 4 R103H PDZ1 1 0/306 France [27]
1069C>T 13 R357W Coiled-coil 1 0/498 This study
CDH23
2263C>T 20 H755Y cd7 1 0/306 USA [56]
3178C>T 26 R1060W cd10 1 0/626 Europe [55]
3565C>T 29 R1189W cd11 1 0/306 This study
4136G>C 33 R1379P cd13 1 0/306 This study
7916A>G 55 D2639G cd25 1 0/306 This study
9127C>T 62 R3043W adjacent to TM
(extracellular)
1 0/490 This study
PCDH15
3817C>A 29 R1273S cd11 1 0/306 This study
USH1G
46C>G 1 L16V 1 0/666 This study
USH2A
653T>A 4 V218E Nter laminin 1 0/306 Great Britain [86]
908G>A 6 R303H Nter laminin 1 0/306 USA [87]
949C>A 6 R317R Nter laminin 1 0/306 Netherlands [60]
1055C>T 6 T352I Nter laminin 1 0/306 Norway [28]
1606T>C 9 C536R 1
st laminin EGF-like 1 0/306 Denmark [81]
1724G>A 10 C575Y 2
nd laminin EGF-
like
1 0/306 This study
3902G>T 18 G1301V 14
th FnIII 1 0/484 This study
8254G>A 42 G2752R 3
rd laminin EGF-like 1 0/306 Japan [88]
9921T>G 50 C3307W 18
th-19
th FnIII 1 0/482 This study
10712C>T 54 T3571M 20
th FnIII 2 0/306 Spain [89]
14426C>T 66 T4809I 33
rd FnIII 1 0/306 Canada [90]
VLGR1
5830G>A 28 D1944N 13
th -14
th b-Calx 1 0/306 This study
10196A>C 49 H3399P 4
th EAR 1 0/306 This study
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Page 9 of 19Seven patients out of 54 (13%) carried two presumably
pathogenic mutations in an USH gene, plus one or two
additional mutations in another USH gene. Taking into
account only the 39 patients for whom biallelic muta-
tions have been identified, 18% (7 out of 39) carry addi-
tional mutations. Specifically, five USH1 patients carried
biallelic mutations in an USH1 gene plus one or two
additional mutations in another USH1 (three patients)
or USH2 (two patients) gene, and two USH2 patients
carried biallelic mutations in USH2 genes plus one addi-
t i o n a l ,p r e s u m a b l yp a t h o g e n i cm u t a t i o ni na nU S H 1o r
an USH2 gene (Table 1). Parents and siblings available
in six out of seven families indeed showed that the two
mutations present in the same gene originated from one
parent each (Figure 3). The mutations found in the
genes that were mutated on both alleles in the patients
consist of two nonsense mutations, five nucleotide dele-
t i o n s ,o n es p l i c es i t em u t a t i o n ,a n dt h r e em i s s e n s e
mutations. The eight additional mutations found in
these patients were amino acid substitutions that were
predicted “probably damaging” and “not tolerated” by
Polyphen and SIFT program, respectively. One of these
mutations, p.R1060W in CDH23, has already been
reported in USH patients [55].
Discussion
The major goal of the study was to design a powerful
and reliable strategy for molecular diagnosis of USH.
For that purpose, some essential, so far missing informa-
tion was gathered by: i) comparing the strategy for
mutation detection currently in use with the here devel-
oped USH exome sequencing (including splice sites), ii)
determination of whether the phenotype can restrict the
mutation screening to the USH genes corresponding to
the clinical subtype in a given patient, and iii) defining
the possible existence of digenic/oligogenic inheritance
of the disease in some patients.
We found mutations in eight of the currently known
nine USH genes, in 49 out of 54 (91%) patients (Table
1). Two or more mutations were identified in 41
patients, including 39 patients (72%) with biallelic muta-
tions, and one mutation was found in the remaining
seven patients (13%), that is a total of 81 different muta-
tions. Current diagnostic strategies use a genotyping
microarray based on the arrayed primer extension
method [24]. Were the international USH genotyping
microarray used to identify the mutations, only 30 out
of the 81 mutations (37%) would have been possibly
detected because of the high prevalence of novel muta-
tions, whatever the USH clinical type. Only 9 mutations
previously reported as recurrent were detected in our
series of patients (i.e. 11% of the mutations), specifically,
c.1996C>T, c.223delG, c.1556G>A, c.494C>T,
c.3719G>A and c.5749G>T in MYO7A, c.238_239dupC
in USH1C, and c.2299delG and c.10712C>T in USH2A.
Therefore, in the process of designing any strategy for
USH molecular diagnosis, taking into account the high
prevalence of novel mutations appears to be of major
importance.
Previous mutation research studies performed in
patients referred to medical genetic clinics showed high
proportions of mutations for MYO7A, CDH23 and
PCDH15 in USH1 patients [27], specifically, 29%-55%
for MYO7A [61-64], 19%-35% for CDH23 [58], 11%-15%
for PCDH15 [65], and for USH2A in USH2 patients
[28,60,66], whereas the implication of VLGR1 and
WHRN in the latter was minor [11,12]. The present ana-
lysis confirms these results by showing a major implica-
tion of MYO7A in USH1 (55% of the cases), and of
USH2A in USH2 (62% of the cases).
Surprisingly, mutations were found in genes that did
not fit the clinically diagnosed USH type. None of the
six patients diagnosed as USH3 on the basis of the post-
lingual onset and progressive nature of the deafness, and
the absence of vestibular dysfunction (see Subjects and
methods) carried a mutation in USH3A.Y e t ,m u t a t i o n s
in USH2 genes were present in all of them, and with a
gene distribution similar to that observed in USH2
patients. This finding, which concerns six out of 24
patients carrying mutations in USH2 genes, calls for a
revision of the USH2 clinical features. Along the same
line, one patient diagnosed as USH2, because he did not
have a vestibular dysfunction, carried biallelic missense
mutations in an USH1 gene, MYO7A.T h et w o
Table 3 Presumably pathogenic DNA variants (Continued)
14119G>T 70 D4707Y 32
nd b-Calx 1 0/446 This study
14654A>G 71 N4885S 32
nd -33
rd b-Calx 1 0/486 This study
16377G>T 77 Q5459H 35
th b-Calx 1 0/402 This study
WHRN
33C>G 1 S11R A/G/S rich region 1 0/494 This study
1135C>T 4 R379W PDZ2 1 0/306 This study
Novel mutations are in bold.
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Page 10 of 19mutations (p.A457V and p. K269del) affect amino acid
residues located in the motor head of myosin VIIa, and
have previously been reported in USH1 patients [63].
They may preserve a residual activity of the protein,
thus causing less severe hearing, balance and visual
impairments. Alternatively, one of these mutations or
both might be deleterious for the myosin VIIa activity
associated with the ankle-link protein complex that
underlies the USH2 phenotype [40], but not with the
transient hair bundle lateral-link and tip-link molecular
complexes that are involved in USH1 pathogenesis.
These phenotype/genotype discrepancies further argue
in favor of a comprehensive mutation screening
Table 4 Distribution of the pathogenic and presumably
pathogenic mutations
Pathogenic and presumably pathogenic mutations
(Novel mutations)
MYO7A 26 (7)
USH1C 3 (1)
CDH23 8 (5)
PCDH15 2 (1)
USH1G 3 (2)
USH2A 25 (9)
VLGR1 11 (11)
WHRN 3 (3)
USH3A 0
Figure 1 Schematic representation of USH1 and USH2 proteins and localization of the novel, presumably pathogenic mutations.T h e
long isoform of each USH protein is shown. *Splice site mutations. Abbreviations: IQ motifs, isoleucine-glutamine motifs; SAH, stable single a-
helix; MyTH4, myosin tail homology 4; FERM, band 4.1-ezrin-radixin-moesin; PDZ, PSD95, discs large, ZO-1; PST, proline-serine-threonine-rich
region; EC, extracellular cadherin; TM, transmembrane domain; Ank, ankyrin domains; cent, central region; SAM, sterile alpha motif; LamG, laminin
G; LamG/TspN/PTX, N-terminal thrombospondin/pentaxin/laminin G-like domain; LamNT, laminin N-terminal; EGF Lam, laminin-type EGF-like; FnIII,
fibronectin type III; VLGR1, very large G protein-coupled receptor 1; Calx,C a
2+-binding calcium exchanger b; EAR, Epilepsy Associated Repeats;
Ala/Gly/Ser rich, alanine, glycine, and serine rich region; Pro rich, proline rich region.
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Page 11 of 19Table 5 Presumably neutral missense variants
Gene Nucleotide change Exon Amino acid change Frequency in
USH alleles
(×/108)
Frequency in
control alleles
References
MYO7A
47T>C 3 L16S >10 [58]
905G>A 9 R302H 2 1/494 [78]
4996A>T 36 S1666C >10 U39226
5156A>G 37 Y1719C* 3 2/306 [91]
5860C>A 43 L1954I >10 U39226
USH1C
2192G>A 21 R731Q 1 This study
2457G>C 24 E819D >10 [92]
CDH23
7C>T 1 R3C >10 [55]
1469G>C 14 G490A >10 [55]
1487G>A 14 S496N >10 [55]
3625A>G 30 T1209A* 1 5/486 [55]
3664G>A 30 A1222T 4 [55]
4051G>A 31 D1351N >10 [55]
4310G>A 34 R1437Q 6 [55]
4723A>G 37 T1575A >10 [55]
4858G>A 38 V1620M 1 2/306 [55]
5023G>A 38 V1675I >10 [55]
5411G>A 41 R1804Q >10 [55]
5418C>G 41 D1806E 2 [93]
5692G>A 42 A1898T 1 0/306 This study
5996C>G 45 T1999S >10 [55]
6130G>A 46 E2044K >10 [55]
6197G>A 46 R2066Q 1 0/306 [55]
6329C>T 47 A2110V 1 This study
6596T>A 47 I2199N 1 0/306 This study
6809G>A 48 R2270H 1 This study
6847G>A 49 V2283I 6 [55]
6869C>T 49 T2290M 1 0/306 This study
7073G>A 50 R2358Q >10 [55]
7139C>T 50 P2380L >10 [55]
7762G>C 54 E2588Q 1 1/306 [55]
9049G>A 61 D3017N 1 This study
9373T>C 65 F3125L 1 7/306 [56]
9949G>A 69 A3317T 1 1/306 This study
PCDH15
55T>G 2 S19A >10 [94]
1039C>T 10 L347F 1 3/666 This study
1138G>A 11 G380S >10 This study
1304A>C 11 D435A >10 AL834134
1910A>G 15 N637S 2 [92]
2786G>A 21 R929Q >10 AL834134
4850A>G 34
§ N1617S 2 This study
4853A>C 36
§ E1618A >10 This study
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Page 12 of 19Table 5 Presumably neutral missense variants (Continued)
4982A>C 37
§ Q1661P >10 This study
USH2A
373G>A 2 A125T >10 [95]
1434G>C 8 E478D 3 [95]
1663C>G 10 L555V* 1 0/306 [96]
1931A>T 11 D644V >10 [95]
4457G>A 21 R1486K >10 AF055580
4994T>C 25 I1665T >10 [89]
6317T>C 32 I2106T >10 [89]
6506T>C 34 I2169T >10 [89]
6713A>C 35 E2238A 6 5/306 [89]
6875G>A 36 R2292H 4 [28]
8624G>A 43 R2875Q 4 [89]
8656C>T 43 L2886F 4 [89]
9008T>C 45 V3003A 1 This study
9262G>A 47 E3088K* 1 3/306 [28]
9296A>G 47 N3099S 4 [89]
9343A>G 47 T3115A 3 5/306 [28]
9430G>A 48 D3144N 4 [89]
9595A>G 49 N3199D 6 [28]
10232A>C 52 E3411A >10 [89]
11504C>T 59 T3835I >10 [28]
11602A>G 60 M3868V >10 [89]
11677C>A 60 P3893T* 1 1/306 [28]
15091C>T 70 R5031W 2 2/306 [28]
15377T>C 71 I5126T* 3 2/306 [87]
VLGR1
365C>T 4 S122L >10 This study
P194H 6 P194H 1 5/468 This study
1033C>A 7 Q345K 1 This study
2261T>C 12 V754A 1 0/306 This study
3289G>A 17 G1097S 1 3/478 This study
3482C>G 19 S1161C 1 0/306 This study
4939A>G 23 I1647V >10 This study
5780C>T 28 T1927M >10 [11]
5851G>A 28 V1951I >10 [11]
5953A>G 28 N1985D >10 [11]
5960C>T 28 P1987L >10 [11]
6012G>T 28 L2004F >10 [11]
6695A>G 30 Y2232C >10 [11]
7034A>G 32 N2345S >10 [11]
7582C>T 33 P2528S 1 1/306 This study
7751A>G 33 N2584S >10 [97]
8291C>T 36 S2764L 6 [11]
8407G>A 37 A2803T 4 [11]
9280G>A 43 V3094I >10 This study
9743G>A 45 G3248D >10 [11]
9650C>T 45 A3217V 2 [11]
10411G>A 49 E3471K >10 [97]
10429G>T 50 D3477Y 1 This study
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Page 13 of 19Figure 2 Segregation of the mutations in MYO7A, USH1G and USH2A in family U3. Arrow indicates the deaf proband.
Table 5 Presumably neutral missense variants (Continued)
10490A>G 50 Q3497R 1 This study
10577T>C 51 M3526T 3 This study
10936T>C 52 S3646P 3 This study
11599G>A 56 E3867K >10 This study
12269C>A 59 T4090N 2 This study
14029T>C 69 F4677L 1 2/478 This study
14905T>C 73 W4969R 2 This study
17626G>A 82 V5876I >10 This study
18475A>G 88 M6159V 2 This study
WHRN
229A>T 1 T77S 1 1/468 [98]
979C>A 4 L327I 1 This study
1318G>A 6 A440T >10 [99]
1838T>C 9 M613T >10 This study
2348T>C 10 V783A >10 [99]
2388C>A 10 N796K >10 [99]
Novel mutations are in bold. * Mutations considered pathogenic by prediction Software, but excluded by segregation studies.
§ Exons 34, 36 and 37 are specific
to isoforms CD1, CD2 and CD3, respectively.
The pathogenicity of several exonic variants found in our patients and predicted to be pathogenic in previous studies and/or by prediction software was further
investigated. The p.T1209A missense mutation in CDH23 has previously been reported in two affected families and considered as pathogenic [55,58]. However,
we found it in five of 486 control alleles from French and Maghreban populations. The p.Y1719C missense mutation in MYO7A seems to represent a frequent
sequence variant in the Moroccan population, with an estimated carrier frequency of 0.07 [100], and was observed in three out of 306 control alleles. The p.
R302H mutation in MYO7A, which affects a residue within a non-conserved region of the motor domain, was detected in one out of 494 control alleles.
Moreover, two of five different MYO7A cDNA clones isolated from three independent libraries were found to encode a histidine residue at codon position 302
[101], which further argues in favor of a non-pathogenic sequence variant. The p.E3088K missense mutation in USH2A, previously described by Dreyer et al., was
present in three out of 306 control alleles, which argues in favor of a non-pathogenic sequence variant [26,28]. The missense mutation p.I5126T in USH2A has
been reported as likely pathogenic [87]. We found it in two USH1 patients, who in addition carried two pathogenic mutations in MYO7A. We detected it in two
individuals from the French control population, suggesting that it is a non-pathogenic sequence variant. The p.L555V mutation in USH2A has been found in
homozygous state in one Spanish patient, together with a biallelic splice site variant (c.1841-2A>G) [26]. Numerous, presumably neutral, isocoding and intronic
variants were also observed (listed in Additional file 2Table S1).
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Page 14 of 19procedure that includes genes seemingly inconsistent
with the clinical classification of USH currently in use.
Notably, our study has revealed one case of likely oli-
gogenic inheritance for USH1, involving MYO7A and
USH1G, and possibly USH2A. Three cases of digenic
inheritance of USH1 have been reported so far [42], all
caused by mutations in CDH23 and PCDH15, in agree-
ment with the contribution of cadherin-23 and proto-
cadherin-15 to the hair bundle transient lateral links
and tip-links [31,32,36,67-69]. The pathogenicity of the
p.T1209A mutation in CDH23 [18,55] is, however, ques-
tionable since we found it in five alleles from the control
population. The c.5601delAAC mutation in PCDH15,
leading to an in frame-deletion of a threonine residue
(p.T1868del) [42] within the intracellular domain of the
protocadherin-15 CD1 isoform, also warrants a special
mention. Three protocadherin-15 isoforms (CD1-3) that
differ in their intracytoplasmic regions have been
reported [69]. Already twop r e s u m a b l yp a t h o g e n i c
mutations (p.M1853L and p.T1868del) [42,70] have
been found in exon 34 that is specific for CD1. Inciden-
tally, the p.T1868del mutation was not only involved in
USH1, but has also been found, in homozygous state, in
a deaf patient presenting with vestibular arreflexia and
without retinitis pigmentosa (C. Bonnet, unpublished).
The CD2 isoform(s) of protocadherin-15 make(s) the
transient kinociliary links [71], whereas the protocad-
herin-15 isoforms that make transient interstereocilia
links and the tip-links are still unknown. The mutations
in exon 34, however, point to an essential biological role
of CD1, or of an as yet uncharacterized protocadherin-
15 isoform that contains the amino acid sequence
encoded by this exon, in the hair cells.
Therefore, even though non-monogenic inheritance of
USH appears to be rare, it has to be taken into consid-
eration in the molecular diagnosis strategy. In addition,
ten patients had presumably pathogenic mutations in
two different USH genes. Seven of them had biallelic
mutations in one gene, and carried an additional muta-
tion in a second and, for one of them, a third USH
gene. None of these additional mutations were nonsense
or frame-shifting mutations, but the conservation of the
corresponding amino acid residues in the orthologous
genes (ush2a, myo7a, whrn)o fCiona savignyi [72], a
cnidarian which is evolutionary distant of about 520
million years from man [73], argues in favor of their
pathogenicity (Figure 4). Notably, these mutations were
not found in 402 to 666 control alleles from populations
of matched geographic origin. A substantial proportion
o fU S Hp a t i e n t st h u sc a r r yat h i r d ,p r e s u m a b l yp a t h o -
genic mutation which, in some cases, may contribute to
worsen the sensory defects resulting from missense
mutations present in the “primary” USH gene.
Finally, no mutations were detected in five patients,
specifically three USH1 and two USH2 patients. In
patient S1823 (USH1), born from consanguineous par-
ents, involvement of any of the nine currently known
USH genes could be excluded by segregation analysis of
polymorphic markers at the corresponding loci (data
not shown). In the four remaining patients, the
Figure 3 Genetic evidence for presumably pathogenic mutations in more than one USH gene in six families. The index case in family
U24 is indicated by an arrow.
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Page 15 of 19undetected mutations might still be located in the unex-
plored promoter regions or intragenic regulatory
sequences of these genes, but may also be located in
other, still unknown USH genes, as in patient S1823.
Indeed, a new locus, USH1H, at chromosome 15q22-23
[74], and three candidate regions for new USH2 genes
(2q32, 4q26 and 15q22-23) have been reported [75].
Conclusion
Direct exon sequencing of a set of specific disease genes
is a reliable, easy set-up method, which remains less
expensive than full exome sequencing in the patients.
Based on the high prevalence of private mutations both
in USH1 and USH2 patients, the substantial number of
cases displaying genotype/phenotype discrepancy, and
the presence of additional,p r e s u m a b l yp a t h o g e n i c
mutations in a number of patients, we conclude that
exon sequencing (including flanking splice sites) of all
c u r r e n t l yk n o w nU S Hg e n e si sr e q u i r e df o rp r o p e r
molecular diagnosis in every USH patient, both in the
context of genetic counseling and in the perspective of
retinal and cochlear gene therapy. The activity of the
USH gene carrying biallelic mutations may indeed turn
o u tt ob eo n l yp a r t l yr e s t o r e db yg e n et h e r a p y ,a n dt h e
presence of a third mutation in another USH gene may
then critically impact on the benefits of the gene ther-
apy. Moreover, as PDZD7 [76] has recently been
reported to modify the phenotype in patients carrying
mutations in USH2A or VLGR1 [77], future studies
should also take into account modifier genes in the
USH exome sequencing strategy.
Additional material
Additional file 1: Figure S1: Sequence alignment of amino acid
residues mutated in patients carrying missense mutations in USH1
genes. Representative stretches of amino acid sequences from each of
the USH1 proteins in various species were aligned. Identical residues are
highlighted with shading. Residues involved in missense mutations are
underlined. Figure S2: Sequence alignment of amino acid residues
mutated in patients carrying missense mutations in USH2 genes.
Representative stretches of amino acid sequences from each of the
USH2 proteins in various species were aligned. Identical residues are
highlighted with shading. Residues involved in missense mutations are
underlined. Orthologs of VLGR1 are not present in the genomes of
invertebrates such as C. elegans and drosophila. Figure S3: Missense
mutations possibly creating or disrupting a splice site.
Representative stretches of amino acid sequences from each of the USH
proteins in various species were aligned. Identical residues are
highlighted with shading. Residues involved in missense mutations are
underlined. Triangles indicate splice sites. Scores for splice sites are
obtained by NetGene2 software program. Possible new splice sites are in
bold. Figure S4: Segregation analysis of the USH2A mutations in
family U51.
Additional file 2: Table S1. Presumably neutral, isocoding and intronic
variants in USH genes.
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